The European Journal of Health Economics最新文献_第8页

The impact of physician-level drug budgets on prescribing behavior 医生层面的药物预算对处方行为的影响

The European Journal of Health Economics Pub Date : 2018-03-01 DOI: 10.1007/s10198-017-0875-9

K. Fischer, T. Koch, K. Kostev, T. Stargardt

引用次数: 9

A methodological framework for assessing agreement between cost-effectiveness outcomes estimated using alternative sources of data on treatment costs and effects for trial-based economic evaluations. 用于评估成本效益结果之间一致性的方法学框架，该结果使用治疗成本的替代数据来源估算，并用于基于试验的经济评估。

The European Journal of Health Economics Pub Date : 2018-01-01 Epub Date: 2017-02-09 DOI: 10.1007/s10198-017-0868-8

Felix Achana, Stavros Petrou, Kamran Khan, Amadou Gaye, Neena Modi

{"title":"A methodological framework for assessing agreement between cost-effectiveness outcomes estimated using alternative sources of data on treatment costs and effects for trial-based economic evaluations.","authors":"Felix Achana, Stavros Petrou, Kamran Khan, Amadou Gaye, Neena Modi","doi":"10.1007/s10198-017-0868-8","DOIUrl":"10.1007/s10198-017-0868-8","url":null,"abstract":"A new methodological framework for assessing agreement between cost-effectiveness endpoints generated using alternative sources of data on treatment costs and effects for trial-based economic evaluations is proposed. The framework can be used to validate cost-effectiveness endpoints generated from routine data sources when comparable data is available directly from trial case report forms or from another source. We illustrate application of the framework using data from a recent trial-based economic evaluation of the probiotic Bifidobacterium breve strain BBG administered to babies less than 31 weeks of gestation. Cost-effectiveness endpoints are compared using two sources of information; trial case report forms and data extracted from the National Neonatal Research Database (NNRD), a clinical database created through collaborative efforts of UK neonatal services. Focusing on mean incremental net benefits at £30,000 per episode of sepsis averted, the study revealed no evidence of discrepancy between the data sources (two-sided p values >0.4), low probability estimates of miscoverage (ranging from 0.039 to 0.060) and concordance correlation coefficients greater than 0.86. We conclude that the NNRD could potentially serve as a reliable source of data for future trial-based economic evaluations of neonatal interventions. We also discuss the potential implications of increasing opportunity to utilize routinely available data for the conduct of trial-based economic evaluations.","PeriodicalId":22450,"journal":{"name":"The European Journal of Health Economics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s10198-017-0868-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82233914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Gender-specific practice styles and ambulatory health care expenditures 针对性别的做法风格和流动医疗保健支出

The European Journal of Health Economics Pub Date : 2017-12-01 DOI: 10.1007/s10198-016-0861-7

Boris Kaiser

引用次数: 1

Health care costs of borderline personality disorder and matched controls with major depressive disorder: a comparative study based on anonymized claims data 基于匿名索赔数据的边缘型人格障碍和匹配对照与重度抑郁症的医疗保健费用比较研究

The European Journal of Health Economics Pub Date : 2017-12-01 DOI: 10.1007/s10198-016-0858-2

Katharina Bode, R. Vogel, J. Walker, C. Kröger

引用次数: 20

Determinants of utilisation differences for cancer medicines in Belgium, Scotland and Sweden. 比利时、苏格兰和瑞典抗癌药物使用差异的决定因素。

The European Journal of Health Economics Pub Date : 2017-12-01 Epub Date: 2016-12-09 DOI: 10.1007/s10198-016-0855-5

Alessandra Ferrario

{"title":"Determinants of utilisation differences for cancer medicines in Belgium, Scotland and Sweden.","authors":"Alessandra Ferrario","doi":"10.1007/s10198-016-0855-5","DOIUrl":"10.1007/s10198-016-0855-5","url":null,"abstract":"Background: Little comparative evidence is available on utilisation of cancer medicines in different countries and its determinants. The aim of this study was to develop a statistical model to test the correlation between utilisation and possible determinants in selected European countries.Methods: A sample of 31 medicines for cancer treatment that obtained EU-wide marketing authorisation between 2000 and 2012 was selected. Annual data on medicines' utilisation covering the in- and out-patient public sectors were obtained from national authorities between 2008 and 2013. Possible determinants of utilisation were extracted from HTA reports and complemented by contacts with key informants. A longitudinal mixed effect model was fitted to test possible determinants of medicines utilisation in Belgium, Scotland and Sweden.Results: In the all-country model, the number of indications reimbursed positively correlated with increased consumption of medicines [one indication 2.6, 95% CI (1.8-3.6); two indications 2.4, 95% CI (1.4-4.3); three indications 4.9, 95% CI (2.2-10.9); all P < 0.01], years since EU-wide marketing authorisation [1.2, 95% CI (1.02-1.4); p < 0.05], price per DDD [0.9, 95% CI (0.998-0.999), P < 0.01], and Prescrire rating [0.5, 95% CI (0.3-0.9), P < 0.05] after adjusting for time and other covariates.Conclusions: In this study, the most important correlates of increased utilisation in a sample of cancer medicines introduced in the past 15 years were: medicines coverage and time since marketing authorisation. Prices had a negative effect on consumption in Belgium and Sweden. The positive impact of financial MEAs in Scotland suggests that the latter may remove the regressive effect of list prices on consumption.","PeriodicalId":22450,"journal":{"name":"The European Journal of Health Economics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641289/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72910796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost analysis and cost-benefit analysis of a medication review with follow-up service in aged polypharmacy patients 老年多药患者用药回顾随访服务的成本分析与成本效益分析

The European Journal of Health Economics Pub Date : 2017-12-01 DOI: 10.1007/s10198-016-0853-7

A. Malet-Larrea, E. Goyenechea, M. A. Gastelurrutia, B. Calvo, V. García-Cárdenas, J. Cabasés, Aránzazu Noain, F. Martínez-Martínez, D. Sabater-Hernández, S. Benrimoj

引用次数: 38

Market approval for drugs in the EU: time to change direction? 欧盟药品市场批准:是时候改变方向了?

The European Journal of Health Economics Pub Date : 2017-11-01 DOI: 10.1007/s10198-016-0863-5

A. Curto, Katelijne de Vooren, L. Garattini

引用次数: 12

Junior doctors’ medical specialty and practice location choice: simulating policies to overcome regional inequalities 初级医生医学专业与执业地点选择:克服地区不平等的模拟政策

The European Journal of Health Economics Pub Date : 2017-11-01 DOI: 10.1007/s10198-016-0846-6

P. Ramos, Hélio Alves, P. Guimarães, M. A. Ferreira

引用次数: 6

The place of DPP-4 inhibitors in the treatment algorithm of diabetes type 2: a systematic review of cost-effectiveness studies DPP-4抑制剂在2型糖尿病治疗算法中的地位:成本-效果研究的系统回顾

The European Journal of Health Economics Pub Date : 2017-11-01 DOI: 10.1007/s10198-016-0837-7

A. Baptista, I. Teixeira, S. Romano, A. Carneiro, J. Perelman

引用次数: 13

Hepatitis C disease transmission and treatment uptake: impact on the cost-effectiveness of new direct-acting antiviral therapies 丙型肝炎疾病传播和治疗吸收:对新型直接作用抗病毒治疗的成本效益的影响

The European Journal of Health Economics Pub Date : 2017-11-01 DOI: 10.1007/s10198-016-0844-8

H. Bennett, J. Gordon, B. Jones, T. Ward, S. Webster, A. Kalsekar, Yong Yuan, M. Brenner, P. McEwan

引用次数: 22